Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Declines By 28.7%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totaling 71,326 shares, a decline of 28.7% from the November 30th total of 100,053 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily volume of 66,726 shares, the short-interest ratio is presently 1.1 days. Based on an average daily volume of 66,726 shares, the short-interest ratio is presently 1.1 days. Currently, 1.1% of the company’s stock are short sold.

Calidi Biotherapeutics Stock Performance

Shares of NYSEAMERICAN:CLDI traded down $0.05 on Monday, hitting $1.19. 167,992 shares of the company’s stock were exchanged, compared to its average volume of 483,012. Calidi Biotherapeutics has a 1-year low of $1.10 and a 1-year high of $19.20. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11. The firm’s 50-day moving average is $1.45 and its 200 day moving average is $2.91.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($2.21) earnings per share for the quarter. On average, equities research analysts forecast that Calidi Biotherapeutics will post -4.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Calidi Biotherapeutics

Institutional investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new stake in Calidi Biotherapeutics during the 1st quarter worth $1,881,000. Belpointe Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics during the first quarter worth about $141,000. Finally, Warberg Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics during the third quarter worth about $28,000. 12.53% of the stock is owned by institutional investors and hedge funds.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.